Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251457 · ClinicalTrials.gov registry record · Phase 1
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
A Phase 1 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02251457 is a Phase 1 study that has completed, run by Ohio State University. The registered enrollment target is 35 participants.
The verdict
NCT02251457, a Phase 1 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251457
The ClinicalTrials.gov registry entry for NCT02251457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT02251457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02251457 about?
NCT02251457 is a clinical study titled "Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1". The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.
What is the current status of trial NCT02251457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-08. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT02251457?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02251457?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.